311 related articles for article (PubMed ID: 8609429)
1. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
Norrby-Teglund A; Kaul R; Low DE; McGeer A; Newton DW; Andersson J; Andersson U; Kotb M
J Immunol; 1996 Apr; 156(8):3057-64. PubMed ID: 8609429
[TBL] [Abstract][Full Text] [Related]
2. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
Darenberg J; Söderquist B; Normark BH; Norrby-Teglund A
Clin Infect Dis; 2004 Mar; 38(6):836-42. PubMed ID: 14999628
[TBL] [Abstract][Full Text] [Related]
3. Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens.
Norrby-Teglund A; Ihendyane N; Kansal R; Basma H; Kotb M; Andersson J; Hammarström L
Clin Infect Dis; 2000 Nov; 31(5):1175-82. PubMed ID: 11073749
[TBL] [Abstract][Full Text] [Related]
4. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
Sriskandan S; Ferguson M; Elliot V; Faulkner L; Cohen J
J Antimicrob Chemother; 2006 Jul; 58(1):117-24. PubMed ID: 16670109
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.
Kaul R; McGeer A; Norrby-Teglund A; Kotb M; Schwartz B; O'Rourke K; Talbot J; Low DE
Clin Infect Dis; 1999 Apr; 28(4):800-7. PubMed ID: 10825042
[TBL] [Abstract][Full Text] [Related]
7. Evidence for superantigen involvement in severe group a streptococcal tissue infections.
Norrby-Teglund A; Thulin P; Gan BS; Kotb M; McGeer A; Andersson J; Low DE
J Infect Dis; 2001 Oct; 184(7):853-60. PubMed ID: 11509997
[TBL] [Abstract][Full Text] [Related]
8. Similar superantigen gene profiles and superantigen activity in norwegian isolates of invasive and non-invasive group a streptococci.
Michaelsen TE; Andreasson IK; Langerud BK; Caugant DA
Scand J Immunol; 2011 Nov; 74(5):423-9. PubMed ID: 21707691
[TBL] [Abstract][Full Text] [Related]
9. Streptococcus pyogenes: Insight into the function of the streptococcal superantigens.
Sriskandan S; Faulkner L; Hopkins P
Int J Biochem Cell Biol; 2007; 39(1):12-9. PubMed ID: 17029999
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G.
Norrby-Teglund A; Kaul R; Low DE; McGeer A; Andersson J; Andersson U; Kotb M
Infect Immun; 1996 Dec; 64(12):5395-8. PubMed ID: 8945593
[TBL] [Abstract][Full Text] [Related]
11. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach.
Norrby-Teglund A; Muller MP; Mcgeer A; Gan BS; Guru V; Bohnen J; Thulin P; Low DE
Scand J Infect Dis; 2005; 37(3):166-72. PubMed ID: 15849047
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG.
Skansén-Saphir U; Andersson J; Björk L; Andersson U
Eur J Immunol; 1994 Apr; 24(4):916-22. PubMed ID: 8149962
[TBL] [Abstract][Full Text] [Related]
13. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy.
Norrby-Teglund A; Basma H; Andersson J; McGeer A; Low DE; Kotb M
Clin Infect Dis; 1998 Mar; 26(3):631-8. PubMed ID: 9524835
[TBL] [Abstract][Full Text] [Related]
14. Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles.
Norrby-Teglund A; Nepom GT; Kotb M
Eur J Immunol; 2002 Sep; 32(9):2570-7. PubMed ID: 12207341
[TBL] [Abstract][Full Text] [Related]
15. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
Norrby-Teglund A; Low DE; McGeer A; Kotb M
Adv Exp Med Biol; 1997; 418():563-6. PubMed ID: 9331714
[No Abstract] [Full Text] [Related]
16. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model.
Tarnutzer A; Andreoni F; Keller N; Zürcher C; Norrby-Teglund A; Schüpbach RA; Zinkernagel AS
Clin Microbiol Infect; 2019 Apr; 25(4):512.e7-512.e13. PubMed ID: 30025835
[TBL] [Abstract][Full Text] [Related]
17. Streptococcal superantigen-induced expansion of human tonsil T cells leads to altered T follicular helper cell phenotype, B cell death and reduced immunoglobulin release.
Davies FJ; Olme C; Lynskey NN; Turner CE; Sriskandan S
Clin Exp Immunol; 2019 Jul; 197(1):83-94. PubMed ID: 30815853
[TBL] [Abstract][Full Text] [Related]
18. A survey of physician's attitudes regarding management of severe group A streptococcal infections.
Valiquette L; Low DE; Chow R; McGeer AJ
Scand J Infect Dis; 2006; 38(11-12):977-82. PubMed ID: 17148064
[TBL] [Abstract][Full Text] [Related]
19. Streptococcal pyrogenic exotoxin A, streptolysin O, exoenzymes, serotype and biotype profiles of Streptococcus pyogenes isolates from patients with toxic shock syndrome and other severe infections.
Müller-Alouf H; Geoffroy C; Geslin P; Bouvet A; Felten A; Günther E; Ozegowski JH; Alouf JE
Zentralbl Bakteriol; 1997 Oct; 286(3):421-33. PubMed ID: 9361388
[TBL] [Abstract][Full Text] [Related]
20. Individual genetic variations directly effect polarization of cytokine responses to superantigens associated with streptococcal sepsis: implications for customized patient care.
Nooh MM; Nookala S; Kansal R; Kotb M
J Immunol; 2011 Mar; 186(5):3156-63. PubMed ID: 21282506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
